Novo Nordisk
NVO
1,864 hedge funds and large institutions have $47.9B invested in Novo Nordisk in 2024 Q2 according to their latest regulatory filings, with 219 funds opening new positions, 761 increasing their positions, 586 reducing their positions, and 79 closing their positions.
177% more first-time investments, than exits
New positions opened: 219 | Existing positions closed: 79
30% more repeat investments, than reductions
Existing positions increased: 761 | Existing positions reduced: 586
14% more capital invested
Capital invested by funds: $41.8B → $47.9B (+$6.06B)
13% more funds holding in top 10
Funds holding in top 10: 80 → 90 (+10)
7% more funds holding
Funds holding: 1,747 → 1,864 (+117)
0.24% more ownership
Funds ownership: 7.29% → 7.53% (+0.24%)
4% less call options, than puts
Call options by funds: $1.09B | Put options by funds: $1.13B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$344M |
| 2 |
MAM
Magellan Asset Management
Sydney,
Australia
|
+$252M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$250M |
| 4 |
Millennium Management
New York
|
+$246M |
| 5 |
DCP
DSM Capital Partners
Palm Beach Gardens,
Florida
|
+$211M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$215M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$118M |
| 3 |
Goldman Sachs
New York
|
-$111M |
| 4 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$99.7M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$96.3M |
NVO Hedge Fund Activity: Q2 2024 in Review
1,864 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q2 2024, worth a combined $47.9B — up 14% from $41.8B a quarter earlier.
Buyers outnumbered sellers: 219 funds opened new NVO positions and 79 closed out — a net gain of 140 holders — while 761 added to existing stakes and 586 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $344M. The largest seller was Renaissance Technologies, cutting an estimated $215M.
- 1,864 institutional investors held Novo Nordisk (NVO) as of Q2 2024, up from 1,747 in Q1 2024.
- Funds reported $47.9B of Novo Nordisk stock for Q2 2024, up 14% quarter-over-quarter.
- 219 funds opened new Novo Nordisk positions in Q2 2024 and 79 closed out, a net change of +140 holders.
- The largest Novo Nordisk buyer in Q2 2024 was Morgan Stanley, an estimated $344M added.
- The largest Novo Nordisk seller in Q2 2024 was Renaissance Technologies, an estimated $215M sold.
Based on aggregated 13F filings for Q2 2024.